CM
CRNX

Castleark Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Castleark Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,790
Closed -$2.92M – 309
2025
Q4 		$2.92M Buy
+62,790
New +$2.8M 0.09% 181
2025
Q1 		– Sell
-77,780
Closed -$3.98M – 297
2024
Q4 		$3.98M Buy
77,780
+4,440
+6% +$248K 0.14% 153
2024
Q3 		$3.75M Buy
+73,340
New +$3.78M 0.15% 141

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Castleark Management's CRNX Position: Q1 2026 in Review

Castleark Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 62,790 shares — an estimated $2.92M sold.

Castleark Management first reported a position in CRNX in Q3 2024 and held it in 3 quarters. The position peaked at $3.98M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Castleark Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Castleark Management sold 62,790 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.92M.
  • Castleark Management first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Castleark Management's Crinetics Pharmaceuticals position peaked at $3.98M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.